Search

USPTO Trademark Application for TRI-VYLIBRA AX

The USPTO has received an intent-to-use trademark application for the mark TRI-VYLIBRA AX, filed on November 12, 2025. The application is for oral contraceptives.

USPTO Trademark Application: TRI-VYLIBRA LO AX

The USPTO has received an intent-to-use trademark application for the mark TRI-VYLIBRA LO AX, filed on November 12, 2025. The application specifies its use in connection with oral contraceptives.

USPTO Trademark Application for VYLIBRA AX

The USPTO has received an intent-to-use trademark application for the mark VYLIBRA AX, filed on November 12, 2025. The application is for oral contraceptives. This filing indicates a future intent to use the mark in commerce.

USPTO Trademark Application for PR PDRN (POLYDEOXYRIBONUCLEOTIDE SODIUM) 10 G

The USPTO has received an intent-to-use trademark application for 'PR PDRN (POLYDEOXYRIBONUCLEOTIDE SODIUM) 10 G'. The application covers pharmaceutical preparations for skin care, including medicated creams and ointments for dermatological use and treating skin disorders.

Yellowbird Diagnostics Intent to Use Trademark Application

The USPTO has received an intent-to-use trademark application from Yellowbird Diagnostics for goods and services related to diagnostic reagents, contrast media, and radiopharmaceuticals. The application was filed on November 12, 2025, with an expected use date of March 22, 2026.

USPTO Trademark Application for ULIFE

The USPTO has received an intent-to-use trademark application for the mark 'ULIFE' filed on November 14, 2025. The application covers dietary supplements, vitamin and mineral supplements, protein supplements, meal replacement drink mixes, and nutraceuticals.

Bybb Lifestyle Root Powders Trademark Published for Opposition

The USPTO has published the trademark application for 'Bybb Lifestyle Root Powders' for opposition. The application, filed on November 14, 2025, is for nutritional supplements and was published on March 22, 2026. This publication opens a period for third parties to oppose the trademark registration.

Fjor Supplements Trademark Published for Opposition

The USPTO has published the trademark application for 'Fjor Supplements' for opposition. The application covers health food and nutritional supplements for health and wellness. The filing date was November 19, 2025, and the publication date is March 22, 2026.

KREAFIX Trademark Application - Intent to Use

The USPTO has received an intent-to-use trademark application for the mark KREAFIX, filed on November 19, 2025. The application covers a range of dietary and nutritional supplements, primarily focused on creatine-based products.

USPTO Trademark Application for Morigella

The USPTO has received an intent-to-use trademark application for the mark "Morigella" by an unnamed applicant. The application covers various dietary supplements and related products. The filing date was November 16, 2025.

THG Teresa Health General Trademark Published for Opposition

The USPTO has published the trademark application for THG Teresa Health General for dietary supplements. The application was published for opposition on March 22, 2026, following a filing date of November 17, 2025. This publication initiates a period during which other parties may oppose the trademark's registration.

FORSYNTH Trademark Application - Intent to Use

The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99497965) for the mark FORSYNTH. The application covers goods and services including dietary supplements, probiotic supplements, and related laboratory research services.

USPTO Trademark Application for IRONMEDS

The USPTO has received an intent-to-use trademark application for the mark IRONMEDS, filed on November 14, 2025. The application covers goods classified as dietary supplements, nutritional supplements, and vitamin supplements.

USPTO Trademark Application 99496083 - Herbal Supplements

The USPTO has received an intent-to-use trademark application (99496083) for herbal supplements. The application was filed on November 13, 2025, and is designated for use with herbal supplements.

USPTO Trademark Application ANIIREM - Intent to Use

The USPTO has published details for an intent-to-use trademark application (TM99505385) for the mark ANIIREM. The application covers various pharmaceutical and herbal products, including herbal tinctures, medicinal preparations, herbal supplements, castor oil for medical purposes, and tea-based beverages.

USPTO Trademark Application for Byheart Baby Food

The USPTO has received an intent-to-use trademark application for 'Byheart' baby food and infant formula. The application was filed on November 13, 2025, and includes the tagline 'THEY’RE NOT IN BREAST MILK, SO THEY’RE NOT IN BYHEART.'

STAYSTRONG+ Trademark Application Filed

The USPTO has received an intent-to-use trademark application for STAYSTRONG+ filed on November 12, 2025. The application covers dietary supplements for humans. This filing indicates a future intention to use the mark in commerce.

USPTO Trademark Application TM99497523 for pharmaceutical preparations

USPTO Trademark Application TM99497523 for pharmaceutical preparations

HSA Singapore: Adverse Effects from Banned Medicinal Products

HSA Singapore has issued a notice regarding adverse effects reported after consumers took banned medicinal products. The agency is highlighting the risks associated with using unapproved health products and urges consumers to exercise caution.

HSA Singapore New Drug Approvals - January 2026

HSA Singapore announced new drug approvals for January 2026. This notice serves to inform stakeholders of the latest additions to the approved drug list.

NARSskin Night Treatment Recalled Due to Sudan IV Detection

The Health Sciences Authority (HSA) of Singapore has initiated a retail-level recall for all batches of NARSskin light reflecting restorative night treatment. The product was found to contain Sudan IV, a substance not permitted in cosmetic products, during a quality surveillance program. Local company Shiseido Singapore Co. (Pte) Limited is instructed to stop supplying the product and return existing stocks.

HSA Singapore SG-eCTD Version 1.1 Package Update

The Health Sciences Authority (HSA) of Singapore has released an updated package for SG-eCTD version 1.1. This update pertains to the electronic Common Technical Document submission format used for regulatory filings.

Keynote on Longevity Innovation, Regulation, and Collaboration

The Health Sciences Authority (HSA) of Singapore has published the text of a keynote address discussing innovation in longevity, the regulatory landscape, and the importance of collaboration. The speech highlights the evolving field of longevity and the need for regulatory frameworks to keep pace with scientific advancements.

MHRA Class 2 Medicines Recall: Hibiwash 500ml due to Microbial Contamination

The MHRA has issued a Class 2 Medicines Recall for Hibiwash 500ml manufactured by Regent Medical Limited / Mölnlycke Health Care due to microbial contamination. Specific batches are affected, and the recall is being conducted to protect public health.

WHO and Partners Launch Digital Health Wallets for ASEAN

The WHO, in partnership with the Temasek Foundation, has launched a three-year initiative to help ASEAN Member States transition from paper-based health records to digital health wallets. This program aims to strengthen national health systems and improve continuity of care by providing trusted, portable access to essential health information.

ANSM Surveillance of Ixchiq Vaccine Adverse Effects

The French National Agency for the Safety of Medicines and Health Products (ANSM) is continuing its surveillance of adverse effects associated with the Ixchiq vaccine, used for chikungunya prevention. This notice serves to inform the public and healthcare professionals about ongoing monitoring activities.

EMA CHMP Meeting Agenda March 2026

The European Medicines Agency (EMA) has published the agenda for the Committee for Medicinal Products for Human Use (CHMP) meeting scheduled for March 23-26, 2026. The agenda outlines 23 procedures, including annual reassessments and Periodic Safety Update Reports (PSURs), for review by the committee.

EMA CHMP Meeting Agenda March 2026

The European Medicines Agency (EMA) has published the agenda for the Committee for Medicinal Products for Human Use (CHMP) meeting scheduled for March 23-26, 2026. The agenda outlines discussions on various medicinal products, including initial applications, oral explanations for pre-authorisation, re-examination, and post-authorisation procedures.

ANSM Safety Recall: Quadripod Cane 548 bis HMS-Vilgo

The French National Agency for Medicines and Health Products Safety (ANSM) has announced a safety recall (R2608257) for the Quadripod cane model 548 bis HMS-Vilgo, initiated by the manufacturer HMS-Vilgo. The recall is directed at pharmacies, healthcare facilities, and home health providers.

ANSM Safety Alert: Space Plus Perfusor Syringe Pump by B Braun

The French National Agency for the Safety of Medicines and Health Products (ANSM) has issued a safety alert regarding the Space Plus Perfusor syringe pump manufactured by B Braun Melsungen AG. This alert informs healthcare facilities and pharmacies about a safety action implemented by the manufacturer.

ANSM Safety Information: Vitros MicroSlide Mg Reagent

The French ANSM has issued a safety alert regarding the Vitros MicroSlide Mg reagent from QuidelOrtho. Affected users have been notified directly by the company, and the action is registered under ANSM number R2607971. This notice provides information and a link to the company's safety communication.

ANSM Safety Information: Thoraflex Hybrid Thoracic Aorta Prosthesis

The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety alert regarding the Thoraflex Hybrid thoracic aorta prosthesis manufactured by Vascutek Ltd. Healthcare providers have been notified of a safety action implemented by the manufacturer.

DEA Seizes 215lbs Meth, Sentences Drug Trafficking Leader

The DEA announced the seizure of over 215 pounds of methamphetamine and the sentencing of Cesar Delfin-Cervantes to nearly 16 years in prison. Delfin-Cervantes was identified as a leader in a multi-state and international drug trafficking organization.

FDA Advisory Letters Notify Firms of Federal Law Violations

The FDA's Center for Veterinary Medicine is posting Untitled Letters on its website to inform the public about firms violating federal law. These letters notify firms of violations that do not meet the threshold for a Warning Letter but still require correction.

FDA CBER Issues Untitled Letters for Violations

The FDA's Center for Biologics Evaluation and Research (CBER) issues untitled letters to regulated industries for violations that do not meet the threshold for a Warning Letter. These letters address issues found in advertising and promotional labeling, bioresearch monitoring, and internet surveillance.

FDA Untitled Letters Issued 2011-2018

The FDA has posted a collection of 83 untitled letters issued between 2011 and 2018 by its Center for Food Safety and Applied Nutrition (CFSAN). These letters address violations related to manufacturing controls or labeling that did not meet the threshold for a Warning Letter.

FDA Untitled Letters to Pharmaceutical Companies

The FDA's CDER Freedom of Information Office has published a list of 34 untitled letters issued to pharmaceutical companies between February 2026 and September 2025. These letters address promotional communications for various prescription drugs, indicating potential violations of FDA regulations regarding drug advertising and promotion.

FDA ART-Plan+ Medical Device Premarket Notification

The FDA has published a premarket notification (510(k)) for the ART-Plan+ medical device. This notification details the device's compliance with regulatory requirements for market entry. The document is part of the FDA's public database for medical device approvals.

FDA PeekMed Radiology Software 510(k) Notification

The FDA has published a 510(k) premarket notification for PeekMed web radiology software. This notification indicates that the software has met the requirements for market entry, allowing it to be used by healthcare providers.

FDA SKOUT system K253664 Medical Device Notification

The FDA has published a 510(k) premarket notification for the SKOUT system (K253664). This notification indicates a new medical device has been cleared for market. Further details on the device's specific function and intended use are available through the provided FDA database link.

FDA K253532: TruSPECT Processing Station Submission

The FDA has published a 510(k) premarket notification submission for the TruSPECT Processing Station, identified by K253532. This notification indicates a new device is being reviewed or has been cleared by the FDA.

FDA 510(k) Premarket Notification - AIR Recon DL

The FDA has published a 510(k) premarket notification for the AIR Recon DL, a device from GE Medical Systems. This notification indicates the device has undergone a review process to demonstrate substantial equivalence to legally marketed predicate devices.

Nuclear Armageddon Trademark Renewal

The United States Patent and Trademark Office (USPTO) has renewed the trademark 'NUCLEAR ARMAGEDDON' (TM87133199) for dietary and nutritional supplements. The renewal is effective March 22, 2026.

AJOSTAR Trademark Renewal

The USPTO has renewed the AJOSTAR trademark (TM87131588), which covers a range of pharmaceutical and medicinal products. The renewal is effective March 22, 2026, and maintains the trademark's protection for its listed goods.

VETONE PROPOVAN CF Trademark Renewal

The United States Patent and Trademark Office (USPTO) has renewed the trademark VETONE PROPOVAN CF, originally filed on August 11, 2016. The renewal is effective March 22, 2026, and pertains to veterinary preparations for animal healthcare, specifically a propofol injection anesthetic.

BEAT IT! Trademark Renewal for Insect Repellents

The USPTO has renewed the trademark 'BEAT IT!' (TM87138736) for insect repellents, with the renewal effective March 22, 2026. The original filing date for this trademark was August 15, 2016.

USPTO Trademark Renewal for Dietary Supplements

The USPTO has renewed trademark application TM87126486 for dietary and nutritional supplements. The renewal is effective March 22, 2026, and continues the protection for a range of supplement products.

USPTO Patent Application: 3D Immunomechanical Organoid Model

The USPTO has published a patent application (US20260079151A1) for a 3D immunomechanical organoid model developed by the University of Notre Dame. This model is designed for observing myeloid cell interactions and for applications in drug screening and microgravity experiments.

USPTO Patent Application: VOCs for Cellular Communication

The USPTO has published patent application US20260079169A1, detailing a method for evaluating cancer behavior using volatile organic compounds (VOCs) detected in a mutual headspace between cancer cells and control samples. The application, filed on November 24, 2025, by inventors from institutions including Technion-Israel Institute of Technology, outlines a novel diagnostic approach.

USPTO Patent Application: Neuron Generation from Pluripotent Stem Cells

The USPTO has published a patent application (US20260079153A1) detailing methods for generating mature neurons from pluripotent stem cells. The disclosed methods involve overexpressing specific splicing factors to facilitate the study of neurodegenerative diseases and the accelerated derivation of mature neurons.